Developer docs
API playgroundTry for free, no card

Search company profiles

Hello Heart

Full company profile

uuid000049j

Namestring
Hello Heart
Legal namestring
Hello Heart, Inc.
Websiteurl
helloheart.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Hello Heart is a digital therapeutics company founded in 2013 and headquartered in Menlo Park, California, focused exclusively on cardiovascular disease management. The company's platform combines FDA-cleared connected blood pressure monitoring hardware with an AI-powered mobile application and a clinical evidence layer validated through peer-reviewed studies. Core products include the Hello Heart App (tracking blood pressure, cholesterol, weight, activity, and medications), the FDA-cleared Hello Heart Monitor, the Nia AI Heart Health Assistant, and the Hello Meds medication management suite including a connected pill box and pharmacist-led medication review service. The platform incorporates AI capabilities for risk detection, behavior change coaching, and personalized medication guidance, operating within clinician-defined guardrails.

The company serves large self-insured employers (500+ employees), Medicare Advantage/commercial health plans, public sector organizations, and labor unions/Taft-Hartley funds. Distribution combines a direct enterprise field-sales motion with embedded channel partnerships through CVS Health (Point Solutions Management program), Aetna, and Elevance/Anthem. Individual end users access the product free through employer or health plan benefits via self-service enrollment. The revenue model is a B2B value-based subscription in which 100% of fees are at-risk tied to clinical and financial outcomes, with a 1.5:1 ROI guarantee for new clients and pricing aligned to enrolled members achieving measurable outcomes.

Hello Heart has raised $138 million in total funding across multiple venture rounds, most recently a $70 million Series D led by Stripes in May 2022, and operates offices in Menlo Park, New York City, Austin, and Tel Aviv. The company reports 225+ employees, 452,000+ subscribers, and has been recognized on the Deloitte Technology Fast 500 (#184) and Inc. 5000 in 2025. Documented outcomes include 47% fewer inpatient hospital days, $1,709 annual savings per participant, 21 mmHg systolic blood pressure reduction over three years for high-risk members, and 42% reduced risk of cardiovascular events.

Short descriptiontext

Hello Heart is a digital therapeutics company that sells AI-powered cardiovascular health management—including FDA-cleared blood pressure monitors, the Nia AI assistant, and medication adherence tools—to large U.S. employers, health plans, public sector organizations, and labor unions on a value-based subscription model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics, cardiovascular health platform, heart health management, connected blood pressure monitoring, employer health benefits
Industry5 codes
PRIMARYHLACAFAA
Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAM
AI/Analytics for RPM (Risk Stratification, Alerts, Predictive)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAPAM
Care Pathway Automation & Patient Engagement for RPM (Coaching, Messaging, Scheduling)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Social Assistance624
SIC code2 codes
  • Services-Health Services8000
  • Services-Home Health Care Services8082
Product category
Digital Health Therapeutics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Enterprise/B2B SaaS Subscription
TypeSubscription Recurring
Description

Value-based pricing model where employers, health plans, and labor unions pay subscription fees for employee/member access to Hello Heart platform. 100% of fees are at-risk based on clinical and financial performance, demonstrating confidence in outcomes. Pricing tied to enrolled members who achieve meaningful outcomes.

helloheart.com
2Individual Access (Employer/Health Plan Sponsored)
TypeFreemium
Description

Free to eligible individuals through employer-sponsored benefits or health plan coverage. Company receives revenue from enterprise clients rather than individual consumers.

helloheart.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Infrastructure
Pricing details1 tier
1Free blood pressure monitor and app for eligible individuals
ModelFreemiumBilling cadenceMonthly
Notes

Available at no cost to individuals whose employers or health plans offer Hello Heart as a benefit. Check eligibility at join.helloheart.com.

helloheart.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Nia
Description

AI Heart Health Assistant - a friendly AI assistant that provides medication and heart health guidance, anytime, integrated into the Hello Heart App

helloheart.com
+3 more records
Core offering1 text field

Hello Heart provides an AI-powered cardiovascular digital therapeutics platform combining an FDA-cleared connected blood pressure monitor, a mobile app, and clinical expertise to help individuals monitor and improve heart health. The platform offers personalized coaching, medication management, AI-driven risk detection, and clinical reporting, and is distributed primarily through enterprise contracts with employers, health plans, public sector organizations, and labor unions on a value-based subscription model.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 21 mmHg reduction in systolic blood pressure over 3 years for high-risk members (84% of participants reduced BP)
+9 more records
Product overview1 text field

Hello Heart is a digital therapeutics platform focused exclusively on cardiovascular health, combining a core mobile app with connected medical devices and AI-powered coaching modules. The product portfolio centers on the Hello Heart App as the primary interface, paired with the FDA-cleared Hello Heart Monitor for blood pressure tracking. AI capabilities are delivered through Nia, the 24/7 heart health assistant, while medication management is handled through Hello Meds, the Hello Heart Pill Box, and the Medication Review Service. The platform integrates these components to provide end-to-end heart health management including tracking, risk detection, personalized coaching, medication adherence, and clinical reporting for employers, health plans, and individuals.

Product and service6 records
1Hello Heart App
CategoryCore Digital Platform
Description

Comprehensive digital hub for managing heart health that tracks blood pressure, cholesterol, weight, activity, and medications; provides personalized coaching; sends reminders; and generates detailed clinical reports for clinicians. Made available to individuals through employer and health plan benefits.

2Hello Heart Monitor
CategoryConnected Medical Device
Description

FDA-cleared blood pressure monitor offering simple one-touch operation with automatic syncing to the Hello Heart app, capturing clinically precise readings for blood pressure, heart rate, and irregular heartbeat detection in a lightweight, portable design.

3Nia: AI Heart Health Assistant
CategoryAI Coaching Module
Description

24/7 AI-powered heart health assistant integrated into the Hello Heart app that provides evidence-based guidance on prescriptions, side effects, drug interactions, and personalized insights based on each member's unique health journey.

4Hello Meds
CategoryMedication Management
Description

Medication management solution that combines an AI assistant, a connected pill box, and pharmacist-led reviews to help members take the right medications consistently and improve medication adherence for heart health.

5Hello Heart Pill Box
CategoryConnected Medical Device
Description

Connected pill box with built-in light indicators that illuminate when it is time to take a dose, syncs directly with the Hello Heart app, has up to 14 compartments, supports a 2-week battery life from a single charge, and tracks medication adherence.

6Medication Review Service
CategoryClinical Service
Description

Pharmacist-led medication review service that identifies potential gaps in therapy, provides evidence-based recommendations to members and their doctors, and is delivered in-app with secure consent-based access and EHR integrations for comprehensive clinical reviews.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

CVS Health Point Solutions Management program partner. CVS simplifies contracting for Hello Heart programs and enables broader distribution through CVS Caremark.

2Aetna (CVS Health subsidiary)
Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

Channel partner simplifying contracting for employer health benefits. Joint webinar on chronic condition gaps and cost containment.

helloheart.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Health plan partner enabling simplified contracting for employer and health plan clients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Independent analysis found $1,434 average reduction in medical costs per member per year. Aon study validates clinical and financial outcomes.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Taft-Hartley benefits consultancy. Segal study shows how one fund scaled digital heart health and reduced costs by $1,434 per member per year.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner. Peer-reviewed study co-authored with UCSF researchers published in JAMA Open Network demonstrating outcomes.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner. Stanford and Hello Heart demonstrated comparable improvements in blood pressure across several social determinants of health.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

AHA Innovators' Network member. Collaboration on advancing cardiovascular health innovation and awareness.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

ACC Industry Advisory Forum member. Strategic collaboration announced March 2026 to advance cardiovascular care.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Medical advisory board member Dr. Erin Michos, MD, MHS - Cardiologist and Director of Women's Cardiovascular Health at Johns Hopkins.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Medical advisory board member Dr. Sharonne Hayes, MD - Vice Chair of Cardiovascular Medicine and Founder of Women's Heart Clinic at Mayo Clinic.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research and advisory collaboration with Dr. Elizabeth Ofili, MD on cardiovascular health equity and women's heart health.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Medical advisory board member Dr. AJ Blood, MD - Cardiologist and Associate Director of Accelerator Clinical Transformation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Omada is a digital chronic care platform offering prevention and management programs for diabetes, hypertension, and behavioral health. It is the closest direct peer to Hello Heart given overlapping customer segments (employers, health plans, public sector), B2B2C value-based pricing, and chronic disease focus; differentiation is Hello Heart's cardiovascular-only specialization.

TypeDirect peer
Description

Virta is a digital therapeutics company that reverses type 2 diabetes and other chronic metabolic conditions through nutrition and remote monitoring. It shares Hello Heart's enterprise channel, value-based contracting, and chronic-disease digital therapeutic model, but addresses cardiometabolic conditions via diabetes reversal rather than BP/cholesterol.

TypeDirect peer
Description

DarioHealth offers a multi-condition digital therapeutics platform for diabetes, hypertension, musculoskeletal, and behavioral health, sold to employers and health plans. It competes with Hello Heart on RPM and chronic disease management with a broader, multi-condition product set.

TypeDirect peer
Description

WellDoc is a digital health company offering AI-driven chronic disease management, with a leading FDA-cleared platform for diabetes. It shares Hello Heart's RPM plus AI-driven coaching model and employer/health plan GTM, with a primary focus on diabetes rather than cardiovascular.

TypeBroad incumbent
Description

Livongo pioneered the chronic-condition digital therapeutics category (initially diabetes, then hypertension) and was acquired by Teladoc. It pioneered the value-based, connected-device-plus-coaching model Hello Heart now operates in, and remains the broad incumbent benchmark for employer-channel digital chronic care.

TypeDirect peer
Description

Hinge Health is a digital musculoskeletal therapeutics company that recently IPO'd, using connected sensors, AI coaching, and value-based pricing for employers and health plans. It shares Hello Heart's digital therapeutic, B2B2C, employer-channel model and recently brought in Hello Heart's new General Counsel from its IPO journey, signaling comparable scale and operating model.

TypeEmerging player
Description

iRhythm is a digital health company that provides ambulatory cardiac monitoring (the Zio patch) with AI-based arrhythmia detection. It overlaps Hello Heart in cardiac focus and connected-device-plus-AI architecture, but is diagnostic/monitoring rather than chronic disease management.

TypeEmerging player
Description

Eko builds AI-powered digital stethoscopes and cardiac monitoring devices with FDA-cleared algorithms for heart sound and ECG analysis. It shares Hello Heart's cardiac specialty and AI/connected-device approach, but is hardware-diagnostic rather than chronic care management.

TypeEmerging player
Description

Withings is a connected health device maker offering smart blood pressure monitors, scales, and wearables integrated with health apps. It overlaps Hello Heart on the FDA-cleared connected BP monitor component and consumer/employer health ecosystems, but does not provide the full coaching or value-based service layer.

TypeBroad incumbent
Description

One Medical is a primary care membership platform acquired by Amazon that combines in-office care with a digital app for chronic and preventive care, including cardiovascular risk management. It represents a broader incumbent alternative for employers and health plans seeking integrated care delivery versus Hello Heart's specialty digital therapeutic.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Hello Heart

Digital Health Therapeuticshelloheart.com

Hello Heart is a digital therapeutics company that sells AI-powered cardiovascular health management—including FDA-cleared blood pressure monitors, the Nia AI assistant, and medication adherence tools—to large U.S. employers, health plans, public sector organizations, and labor unions on a value-based subscription model.

What Hello Heart does

Hello Heart is a digital therapeutics company founded in 2013 and headquartered in Menlo Park, California, focused exclusively on cardiovascular disease management. The company's platform combines FDA-cleared connected blood pressure monitoring hardware with an AI-powered mobile application and a clinical evidence layer validated through peer-reviewed studies. Core products include the Hello Heart App (tracking blood pressure, cholesterol, weight, activity, and medications), the FDA-cleared Hello Heart Monitor, the Nia AI Heart Health Assistant, and the Hello Meds medication management suite including a connected pill box and pharmacist-led medication review service. The platform incorporates AI capabilities for risk detection, behavior change coaching, and personalized medication guidance, operating within clinician-defined guardrails.

The company serves large self-insured employers (500+ employees), Medicare Advantage/commercial health plans, public sector organizations, and labor unions/Taft-Hartley funds. Distribution combines a direct enterprise field-sales motion with embedded channel partnerships through CVS Health (Point Solutions Management program), Aetna, and Elevance/Anthem. Individual end users access the product free through employer or health plan benefits via self-service enrollment. The revenue model is a B2B value-based subscription in which 100% of fees are at-risk tied to clinical and financial outcomes, with a 1.5:1 ROI guarantee for new clients and pricing aligned to enrolled members achieving measurable outcomes.

Hello Heart has raised $138 million in total funding across multiple venture rounds, most recently a $70 million Series D led by Stripes in May 2022, and operates offices in Menlo Park, New York City, Austin, and Tel Aviv. The company reports 225+ employees, 452,000+ subscribers, and has been recognized on the Deloitte Technology Fast 500 (#184) and Inc. 5000 in 2025. Documented outcomes include 47% fewer inpatient hospital days, $1,709 annual savings per participant, 21 mmHg systolic blood pressure reduction over three years for high-risk members, and 42% reduced risk of cardiovascular events.

Hello Heart firmographics

Firmographics
Name
Hello Heart
Legal name
Hello Heart, Inc.
Website
https://helloheart.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Hello Heart is a digital therapeutics company that sells AI-powered cardiovascular health management—including FDA-cleared blood pressure monitors, the Nia AI assistant, and medication adherence tools—to large U.S. employers, health plans, public sector organizations, and labor unions on a value-based subscription model.
Ownership category
akta.pro rank

Hello Heart industry classification

Industry
Product category
Digital Health Therapeutics
NAICS
Social Assistance (624)
SIC
Services-Health Services (8000), Services-Home Health Care Services (8082)
akta.pro industry
PRIMARYHLACAFAA
Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAM
AI/Analytics for RPM (Risk Stratification, Alerts, Predictive)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAPAM
Care Pathway Automation & Patient Engagement for RPM (Coaching, Messaging, Scheduling)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Digital therapeutics
  • Cardiovascular health platform
  • Heart health management
  • Connected blood pressure monitoring
  • Employer health benefits

Where Hello Heart is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Hello Heart business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain, Infrastructure

Revenue model

  1. Enterprise/B2B SaaS Subscription: Value-based pricing model where employers, health plans, and labor unions pay subscription fees for employee/member access to Hello Heart platform. 100% of fees are at-risk based on clinical and financial performance, demonstrating confidence in outcomes. Pricing tied to enrolled members who achieve meaningful outcomes.
  2. Individual Access (Employer/Health Plan Sponsored): Free to eligible individuals through employer-sponsored benefits or health plan coverage. Company receives revenue from enterprise clients rather than individual consumers.

Pricing tiers

ModelBillingPrice
FreemiumMonthlyFree blood pressure monitor and app for eligible individuals

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Hello Heart product offering

Product offering

Core offering

Hello Heart provides an AI-powered cardiovascular digital therapeutics platform combining an FDA-cleared connected blood pressure monitor, a mobile app, and clinical expertise to help individuals monitor and improve heart health. The platform offers personalized coaching, medication management, AI-driven risk detection, and clinical reporting, and is distributed primarily through enterprise contracts with employers, health plans, public sector organizations, and labor unions on a value-based subscription model.

Product overview

Hello Heart is a digital therapeutics platform focused exclusively on cardiovascular health, combining a core mobile app with connected medical devices and AI-powered coaching modules. The product portfolio centers on the Hello Heart App as the primary interface, paired with the FDA-cleared Hello Heart Monitor for blood pressure tracking. AI capabilities are delivered through Nia, the 24/7 heart health assistant, while medication management is handled through Hello Meds, the Hello Heart Pill Box, and the Medication Review Service. The platform integrates these components to provide end-to-end heart health management including tracking, risk detection, personalized coaching, medication adherence, and clinical reporting for employers, health plans, and individuals.

Differentiator

Problem solved

Functional benefit

Brands

  • Nia: AI Heart Health Assistant - a friendly AI assistant that provides medication and heart health guidance, anytime, integrated into the Hello Heart App
  • Hello Meds
  • Hello Heart Monitor
  • Hello Heart Pill Box

Products and services

  • Hello Heart App Comprehensive digital hub for managing heart health that tracks blood pressure, cholesterol, weight, activity, and medications; provides personalized coaching; sends reminders; and generates detailed clinical reports for clinicians. Made available to individuals through employer and health plan benefits.
  • Hello Heart Monitor FDA-cleared blood pressure monitor offering simple one-touch operation with automatic syncing to the Hello Heart app, capturing clinically precise readings for blood pressure, heart rate, and irregular heartbeat detection in a lightweight, portable design.
  • Nia: AI Heart Health Assistant 24/7 AI-powered heart health assistant integrated into the Hello Heart app that provides evidence-based guidance on prescriptions, side effects, drug interactions, and personalized insights based on each member's unique health journey.
  • Hello Meds Medication management solution that combines an AI assistant, a connected pill box, and pharmacist-led reviews to help members take the right medications consistently and improve medication adherence for heart health.
  • Hello Heart Pill Box Connected pill box with built-in light indicators that illuminate when it is time to take a dose, syncs directly with the Hello Heart app, has up to 14 compartments, supports a 2-week battery life from a single charge, and tracks medication adherence.
  • Medication Review Service Pharmacist-led medication review service that identifies potential gaps in therapy, provides evidence-based recommendations to members and their doctors, and is delivered in-app with secure consent-based access and EHR integrations for comprehensive clinical reviews.

Quantifiable outcome

  • 21 mmHg reduction in systolic blood pressure over 3 years for high-risk members (84% of participants reduced BP)
  • +9 more outcomes

Companies that use Hello Heart

Customer profile

Named customers14 records

Segments5 records

Ideal customer profiles4 records

Hello Heart technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability8 records

Feature5 records

Hello Heart partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered flagship, core and minor.

  • CVS HealthflagshipChannel Partner/ Reseller/ DistributorCVS Health Point Solutions Management program partner. CVS simplifies contracting for Hello Heart programs and enables broader distribution through CVS Caremark.
  • Aetna (CVS Health subsidiary)flagshipChannel Partner/ Reseller/ DistributorChannel partner simplifying contracting for employer health benefits. Joint webinar on chronic condition gaps and cost containment.
  • Elevance Health (Anthem)coreChannel Partner/ Reseller/ DistributorHealth plan partner enabling simplified contracting for employer and health plan clients.
  • AoncoreStrategic or Co-development PartnerIndependent analysis found $1,434 average reduction in medical costs per member per year. Aon study validates clinical and financial outcomes.
  • SegalminorStrategic or Co-development PartnerTaft-Hartley benefits consultancy. Segal study shows how one fund scaled digital heart health and reduced costs by $1,434 per member per year.
  • UCSFcoreStrategic or Co-development PartnerResearch partner. Peer-reviewed study co-authored with UCSF researchers published in JAMA Open Network demonstrating outcomes.
  • Stanford UniversitycoreStrategic or Co-development PartnerResearch partner. Stanford and Hello Heart demonstrated comparable improvements in blood pressure across several social determinants of health.
  • American Heart AssociationcoreStrategic or Co-development PartnerAHA Innovators' Network member. Collaboration on advancing cardiovascular health innovation and awareness.
  • American College of CardiologycoreStrategic or Co-development PartnerACC Industry Advisory Forum member. Strategic collaboration announced March 2026 to advance cardiovascular care.
  • Johns Hopkins MedicinecoreStrategic or Co-development PartnerMedical advisory board member Dr. Erin Michos, MD, MHS - Cardiologist and Director of Women's Cardiovascular Health at Johns Hopkins.
  • Mayo CliniccoreStrategic or Co-development PartnerMedical advisory board member Dr. Sharonne Hayes, MD - Vice Chair of Cardiovascular Medicine and Founder of Women's Heart Clinic at Mayo Clinic.
  • Morehouse School of MedicinecoreStrategic or Co-development PartnerResearch and advisory collaboration with Dr. Elizabeth Ofili, MD on cardiovascular health equity and women's heart health.
  • Brigham and Women's HospitalcoreStrategic or Co-development PartnerMedical advisory board member Dr. AJ Blood, MD - Cardiologist and Associate Director of Accelerator Clinical Transformation.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Hello Heart competitors and assessment

Company assessment

Direct peers

  • Omada Health: Omada is a digital chronic care platform offering prevention and management programs for diabetes, hypertension, and behavioral health. It is the closest direct peer to Hello Heart given overlapping customer segments (employers, health plans, public sector), B2B2C value-based pricing, and chronic disease focus; differentiation is Hello Heart's cardiovascular-only specialization.
  • Virta Health: Virta is a digital therapeutics company that reverses type 2 diabetes and other chronic metabolic conditions through nutrition and remote monitoring. It shares Hello Heart's enterprise channel, value-based contracting, and chronic-disease digital therapeutic model, but addresses cardiometabolic conditions via diabetes reversal rather than BP/cholesterol.
  • DarioHealth: DarioHealth offers a multi-condition digital therapeutics platform for diabetes, hypertension, musculoskeletal, and behavioral health, sold to employers and health plans. It competes with Hello Heart on RPM and chronic disease management with a broader, multi-condition product set.
  • WellDoc: WellDoc is a digital health company offering AI-driven chronic disease management, with a leading FDA-cleared platform for diabetes. It shares Hello Heart's RPM plus AI-driven coaching model and employer/health plan GTM, with a primary focus on diabetes rather than cardiovascular.
  • Hinge Health: Hinge Health is a digital musculoskeletal therapeutics company that recently IPO'd, using connected sensors, AI coaching, and value-based pricing for employers and health plans. It shares Hello Heart's digital therapeutic, B2B2C, employer-channel model and recently brought in Hello Heart's new General Counsel from its IPO journey, signaling comparable scale and operating model.

Broad incumbents

  • Livongo (Teladoc Health): Livongo pioneered the chronic-condition digital therapeutics category (initially diabetes, then hypertension) and was acquired by Teladoc. It pioneered the value-based, connected-device-plus-coaching model Hello Heart now operates in, and remains the broad incumbent benchmark for employer-channel digital chronic care.
  • 1Life Healthcare (One Medical, Amazon): One Medical is a primary care membership platform acquired by Amazon that combines in-office care with a digital app for chronic and preventive care, including cardiovascular risk management. It represents a broader incumbent alternative for employers and health plans seeking integrated care delivery versus Hello Heart's specialty digital therapeutic.

Emerging players

  • iRhythm Technologies: iRhythm is a digital health company that provides ambulatory cardiac monitoring (the Zio patch) with AI-based arrhythmia detection. It overlaps Hello Heart in cardiac focus and connected-device-plus-AI architecture, but is diagnostic/monitoring rather than chronic disease management.
  • Eko Health: Eko builds AI-powered digital stethoscopes and cardiac monitoring devices with FDA-cleared algorithms for heart sound and ECG analysis. It shares Hello Heart's cardiac specialty and AI/connected-device approach, but is hardware-diagnostic rather than chronic care management.
  • Withings: Withings is a connected health device maker offering smart blood pressure monitors, scales, and wearables integrated with health apps. It overlaps Hello Heart on the FDA-cleared connected BP monitor component and consumer/employer health ecosystems, but does not provide the full coaching or value-based service layer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Hello Heart social profiles

Digital presence

Hello Heart compliance and trust

Trust signal

Compliance2 records

Hello Heart financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Hello Heart leadership team

Management profile

Number of profiles

Profiles12 records

Hello Heart funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Hello Heart M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hello Heart

What does Hello Heart do?

Hello Heart provides an AI-powered cardiovascular digital therapeutics platform combining an FDA-cleared connected blood pressure monitor, a mobile app, and clinical expertise to help individuals monitor and improve heart health. The platform offers personalized coaching, medication management, AI-driven risk detection, and clinical reporting, and is distributed primarily through enterprise contracts with employers, health plans, public sector organizations, and labor unions on a value-based subscription model.

Is Hello Heart a public or private company?

Hello Heart is a private company. It is classified as venture growth investor backed and is currently operating.

When was Hello Heart founded?

Hello Heart was founded in 2015. It employs 501 to 1,000 people.

Where is Hello Heart based?

Hello Heart is headquartered in Menlo Park, United States, in the North America region.

How does Hello Heart make money?

Two revenue lines are on record. Enterprise/B2B SaaS Subscription is the primary driver. The others are individual Access (Employer/Health Plan Sponsored).

Who are Hello Heart's main competitors?

Direct peers on record are Omada Health, Virta Health, DarioHealth, WellDoc and Hinge Health. Broad incumbents are Livongo (Teladoc Health) and 1Life Healthcare (One Medical, Amazon). Emerging players are iRhythm Technologies, Eko Health and Withings.

Does Hello Heart have an API?

No public API is recorded for Hello Heart.

What industry is Hello Heart in?

Hello Heart's product category is Digital Health Therapeutics. Its primary akta.pro industry code is HLACAFAA, Chronic Disease RPM Platforms (Diabetes/HTN/COPD/CHF), with a secondary code of HLACAFAM, AI/Analytics for RPM (Risk Stratification, Alerts, Predictive). Its NAICS code is 624 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogHello Heart Takes On the High Cost of Heart Failure With Hello GuardHello Heart launched Hello Guard, a heart failure offering with connected devices, AI, and cardiologist-led virtual care. Research links Hello Heart to about $7,000 lower medical spending per member with heart failure, and the company cites 47 fewer inpatient admissions per 100 participants.FinancialContent Business PageHello Heart Names Longtime HubSpot Finance Executive Charles MacGlashing CFO as Company Accelerates GrowthHello Heart appointed Charles MacGlashing as CFO after his decade at HubSpot. The company grew committed annual recurring revenue by 50% in 2025 and expects similar growth in 2026. MacGlashing will lead finance and strategy as Hello Heart expands.MorningstarHello Heart Study Finds $7K Lower Medical Spend and Fewer Hospitalizations for Users With Heart FailureA study published in Value in Health found Hello Heart's AI-driven heart health program reduced medical spend by $7,001 per participant and cut inpatient admissions by 47 per 100 participants. The analysis of 292 matched participants showed 297 fewer inpatient days and 139 additional primary care visits.Tracxn2026 Funding Rounds & List of InvestorsThe article presents a tabular list of historical funding rounds for the company Hello Heart, detailing dates, amounts, and investors from 2015 to 2022. It lists specific venture capital firms such as Khosla Ventures, BlueRun Ventures, and Resolute Ventures as lead investors in various Series A through D rounds.Business Wire BlogNew Study Shows Hello Heart Reduces Socioeconomic Gaps in Cardiovascular CareA study published in the American Heart Association’s Circulation indicates that Hello Heart’s digital cardiovascular program achieved higher enrollment and comparable engagement among lower-income residents compared to their higher-income counterparts. The research found that participation was associated with increased primary care visits and reduced avoidable emergency department visits across all socioeconomic groups studied.FierceHealthcare'Missed risk': Women's Heart Health Summit explores gaps in research, treatmentHello Heart hosted the annual Women’s Heart Health Summit in Boca Raton, bringing together healthcare stakeholders to address gaps in research and treatment for women's cardiovascular disease. Speakers highlighted significant funding cuts from the NIH under the Trump administration, prompting organizations like Amgen to increase their support for research grants. The event also emphasized the potential of AI technology in risk prediction while stressing the need for inclusive design and provider trust.Fast CompanyThe most innovative emerging enterprises of 2026Fast Company has released its 2026 list of Most Innovative Companies, profiling 10 emerging enterprises with 201-999 employees that are leveraging AI and technology to disrupt their respective industries, including threat intelligence firm Strider Technologies, heart health platform Hello Heart, semiconductor company Axelera AI, philanthropy software provider Foundation Source, radiology AI firm Rad AI, Hispanic food supplier Vilore Foods, backup power company Kenerator, creative agency R/GA, property management software firm Lessen, and financial AI company Daloopa. The profiled companies span sectors from healthcare and fintech to semiconductors and philanthropy, with many doubling revenue, expanding headcount, or launching new AI-powered products over the past year.Business Wire BlogNational Survey Finds Heart Conditions Top Cost Driver for Employers and Health Plans, But Action to Contain Costs LagsHello Heart released its 2026 Heart Health Matters Report based on a survey of 400 benefits leaders, finding that while 91% recognize heart disease as a top cost driver generating $9.3K average annual medical costs per affected person, only about one-third rank heart disease prevention as a top benefits priority. The report reveals a significant action gap: only 32% of respondents feel prepared to manage increases in heart health claims costs in 2026, despite 87% of employer leaders and 85% of health plan leaders believing indirect costs of unmanaged heart disease exceed direct claims. The company highlights that up to 80% of heart attacks and strokes are preventable through earlier intervention, digital health tools, and improved medication adherence.The Global Legal PostUS digital healthcare provider Hello Heart hires GC from Hinge HealthHello Heart, a Menlo Park-based digital healthcare company focused on cardiovascular health technology, has appointed David Wood as its new general counsel, succeeding Dwight Moxie. Wood joins from Hinge Health where he served as GC and brings more than two decades of legal and regulatory experience in digital health, having played a key role in scaling Hinge Health through rapid growth and its recent IPO. His appointment comes amid a broader trend of in-house legal appointments at US healthcare and biotech companies.Revelio LabsHello Heart Number of Employees 2026 | Employee Count & Headcount DataHello Heart, Inc. has approximately 680 total employees worldwide as of March 2026, representing a 21.9% growth from its 558 employees in 2023. The company is actively hiring, with active job postings increasing by 97.3% to 55 in 2026 compared to the previous year.